PT suppressed overexpression of NF-E2-related factor 2 (Nrf2) and its related genes that prevented development of resistance to mitoxantrone and doxorubicin in triple-negative breast cancer (Carlisi et al., 2017). This evidence concerns the gene NFE2L2 and triple-negative breast carcinoma.